A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis

Journal of Pediatric Ophthalmology and Strabismus

Volumn 45, Issue 6, 2008, Pages 340-349

  Granet, David B ^a   Dorfman, Mark ^b   Stroman, David ^c   Cockrum, Paul ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOE DIMAGGIO CHILDREN S HOSPITAL   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; POLYTRIM; EYE DROPS; HETEROCYCLIC COMPOUND; POLYMYXIN B; QUINOLINE DERIVATIVE; TOPICAL ANTIINFECTIVE AGENT; TRIMETHOPRIM;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORYNEBACTERIUM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS FAECALIS; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; OTITIS MEDIA; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TELEPHONE; VIRUS INFECTION; BACTERIUM; DRUG COMBINATION; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFECTIVE AGENTS, LOCAL; AZA COMPOUNDS; BACTERIA; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, BACTERIAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALE; OPHTHALMIC SOLUTIONS; POLYMYXIN B; QUINOLINES; TREATMENT OUTCOME; TRIMETHOPRIM;

EID: 58149308511     PISSN: 01913913     EISSN: None     Source Type: Journal    
DOI: 10.3928/01913913-20081101-07     Document Type: Article

References (40)

1. Gigliotti F, Williams WT, Hayden FG, et al. Etiology of acute conjunctivitis in children. J Pediatr. 1981;98:531-536.
2. Weiss A, Brinser JH, Nazar-Stewart V. Acute conjunctivitis in children. J Pediatr. 1993;122:10-14.
3. Patel PB, Diaz MC, Bennett JE, Attia MW. Clinical features of bacterial conjunctivitis in children. Acad Emerg Med. 2007;14:1-5.
4. Soukiasian SH, Baum J. Bacterial conjunctivitis. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. St. Louis: Mosby-Year Book; 1997:2759-3172.
5. Hwang DG. Bacterial conjunctivitis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection & Immunity. St. Louis: Mos-by-Year Book; 1996:799-817.
6. Smith AF, Waycaster C. The annual cost of bacterial conjunctivitis in the United States: evidence from an economic modeling approach. Value in Health. 2008;11:A291.
7. Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med. 2003;348:1112-1121.
8. Centers for Disease Control and Prevention. Outbreak of bacterial conjunctivitis at a college - New Hampshire, January-March, 2002. MMWR. 2002;51:205-207.
9. Centers for Disease Control and Prevention. Pneumococcal conjunctivitis at an elementary school - Maine, September 20-December 6, 2002. MMWR. 2003;52:64-66.
10. Minnesota Department of Health. Outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. Disease Control Newsletter. 2004;32:6-8.
11. Trottier S, Stenberg K, Von Rosen IA, Svanborg C. Haemophilus influenzae causing conjunctivitis in day-care children. Pediatr Infect Dis J. 1991;10:578-584.
12. Lichtenstein SJ, Wagner RS, Jamison T, Bell B, Stroman DW. Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies. Adv Ther. 2007;24:1098-1111.
13. Gigliotti F, Hendley JO, Morgan J, Michads R, Dikens M, Lohr J. Efficacy of topical antibiotic therapy in acute conjunctivitis in children. J Pediatr. 1984;104:623-626.
14. Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT, Levofloxacin Bacterial Conjunctivitis Active Control Study Group. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology. 2003;110:457-465.
15. Adenis JP, Brasseur G, Demailly P, et al. Comparative evaluation of efficacy and safety of ciprofloxacin and norfloxacin ophthalmic solution. Eur J Ophthalmol. 1996;6:287-292.
16. Ogawa GS, Hyndiuk RA. The fluoroquinolones: new antibiotics in ophthalmology. Int Ophthalmol Clin. 1993;33:59-68.
17. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol. 1999;2:504-508.
18. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother. 1997;41:101-106.
19. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother. 1997;41:101-106.
20. Lichtenstein SJ, Dorfman M, Kennedy R, Stroman D. Controlling contagious bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2006;43:19-26.
21. Mah FS. New antibiotics for bacterial infections. Ophthalmol Clin North Am. 2003;16:11-27.
22. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004;49(suppl 2):S79-S83.
23. O'Brien TP. Evidence-based review of moxifloxacin. Int Ophthal-tool Clin. 2006;46:61-72.
24. Kowalski RP, Yates KA, Romanwski EG, Karenchak LM, Mah FS, Gordon YJ. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 2005;112:1987-1991.
25. Wagner RS, Abelson MB, Shapiro A, Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissues. Arch Ophthalmol. 2005;123:1282-1283.
26. Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin ophthalmic solution 0.5% Vigamox® in pediatric and non-pediatric patients with bacterial conjunctivitis. Surv Ophthalmol. 2005;50(suppl 1):S55-S63.
27. Blondeau JM, Hansen G, Metzler K, Hedlin E The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother. 2004;16(suppl 3): S1-S19.
28. Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol. 2004;15:316-320.
29. Everitt HA, Little PS, Smith PW. A randomized controlled trial of management strategies for acute infective conjunctivitis in general practice. BMJ. 2006;333:321. Erratum in: BMJ. 2006;333:468.
30. Ohnsman CM. Exclusion of students with conjunctivitis from school: policies of state departments of health. J Pediatr Ophthalmol Strabismus. 2007;44:101-105.
31. American Academy of Pediatrics. Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: Author; 2003:141-142.
32. American Public Health Association. Conjunctivitis/keratitis. In: Heymann DL, ed. Control of Communicable Disease Manual. 18th ed. Washington, DC: Author; 2004:124-130.
33. Adams PF, Hendershot G, Marano MA. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital and Health Statistics. 1999;10:1-203.
34. Coalition to Invest in Texas Schools. School funding 101. Available at: http://www.investintexasschools.org/schoolfunding/glossary.php. Accessed September 10, 2008.
35. Williams LL. Student absenteeism and truancy: technologies and interventions to reduce and prevent chronic problems among school-age children. Available at: http://chiron.valdosta.edu/are/Litreviews/ vol1no1/williams_litr.pdf. Accessed September 22, 2008.
36. Poway Unified School District. Increasing student attendance increases funding to schools: a bonus for the school district if parents and children assist. Available at: http://www.powayusd.com/news/ attendance.htm. Accessed September 10, 2008.
37. San Diego Unified School District. Pupil accounting. Available at: http://www.sandi.net/pupil_acct/. Accessed September 10, 2008.
38. Big plans on campus. Business Week. Fall 2004. Available at: http://www.businessweek.com/magazine/content/04_44/b3906650.htm. Accessed September 10, 2008.
39. Price R. 13 years without missing school? Somebody take his temperature. The Bakersfield Californian. May 31, 2008. Available at: http://www.bakersfield.com/opinion/columnists/rober_prtice/story/ 459418.html. Accessed September 10, 2008.
40. Waycaster C. A cost-effectiveness analysis of two topical ophthalmic antibiotic solutions indicated for the treatment of bacterial conjunctivitis. Value in Health. 2008;11:A289.